Loading...

Salusky Isidro

Title(s)Co-Chair, Participant and Clinical Interaction and Resources Program
SchoolCTSI
Phone(310) 206-6987
vCardDownload vCard
    Other Positions
    Title(s)Professor, Pediatrics

    Title(s)Director, Clinical & Translational Research Laboratory

    Title(s)Director, Hemodialysis and Peritoneal Dialysis Service

    Title(s)Chief, Pediatric Nephrology

    Title(s)Director, General Clinical Research Center


    Collapse Research 
    Collapse Research Activities and Funding
    Phosphate Binders in Children with Chronic Kidney Disease-Mineral Bone Disorder
    NIH/NIDDK U34DK104619Aug 1, 2015 - Jul 31, 2016
    Role: Principal Investigator
    Translational Research Training in Pediatric Nephrology
    NIH/NIDDK T32DK104687Jul 1, 2015 - Jun 30, 2020
    Role: Principal Investigator
    Role of Parathyroid Hormone in Renal Osteodystrophy
    NIH/NIDDK R01DK067563Feb 15, 2005 - Jan 31, 2012
    Role: Principal Investigator
    UCLA Graduate Training Program in Translational and Clinical Investigation
    NIH/NCRR K30RR022259Sep 30, 2000 - Aug 26, 2012
    Role: Principal Investigator
    ENDOCHONDRAL BONE FORMATION IN RENAL FAILURE
    NIH/NIDDK R21DK053655Jan 1, 1998 - Dec 31, 1999
    Role: Principal Investigator
    Regulation of Bone Mineralization in Renal Osteodystrophy
    NIH/NIDDK R01DK035423Jan 1, 1986 - Jun 30, 2014
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Laster M, Pereira RC, Salusky IB. Unraveling the osteocyte in CKD-MBD post-renal transplantation. Kidney Int. 2019 Nov; 96(5):1059-1061. PMID: 31648693.
      View in: PubMed
    2. Pereira RC, Salusky IB, Bowen RE, Freymiller EG, Wesseling-Perry K. Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone. Bone. 2019 Oct; 127:626-634. PMID: 31377240.
      View in: PubMed
    3. Okuda Y, Obi Y, Streja E, Laster M, Rhee C, Langman CB, Jernigan SM, Salusky IB, Tentori F, Schreiber MJ, Brunelli SM, Kalantar-Zadeh K. Serum albumin and hospitalization among pediatric patients with end-stage renal disease who started dialysis therapy. Pediatr Nephrol. 2019 Oct; 34(10):1799-1809. PMID: 31218394.
      View in: PubMed
    4. Laster M, Pereira RC, Salusky IB. Racial differences in bone histomorphometry in children and young adults treated with dialysis. Bone. 2019 Oct; 127:114-119. PMID: 31181383.
      View in: PubMed
    5. Ganz T, Bino A, Salusky IB. Mechanism of Action and Clinical Attributes of Auryxia® (Ferric Citrate). Drugs. 2019 Jun; 79(9):957-968. PMID: 31134521.
      View in: PubMed
    6. Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA. Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to
      View in: PubMed
    7. Hanudel MR, Laster M, Salusky IB. Non-renal-Related Mechanisms of FGF23 Pathophysiology. Curr Osteoporos Rep. 2018 12; 16(6):724-729. PMID: 30353318.
      View in: PubMed
    8. Pereira RC, Salusky IB, Roschger P, Klaushofer K, Yadin O, Freymiller EG, Bowen R, Delany AM, Fratzl-Zelman N, Wesseling-Perry K. Impaired osteocyte maturation in the pathogenesis of renal osteodystrophy. Kidney Int. 2018 11; 94(5):1002-1012. PMID: 30348285.
      View in: PubMed
    9. Laster M, Soohoo M, Streja E, Elashoff R, Jernigan S, Langman CB, Norris KC, Salusky IB, Kalantar-Zadeh K. Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis. Pediatr Nephrol. 2019 01; 34(1):107-115. PMID: 30267239.
      View in: PubMed
    10. Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA. An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to
      View in: PubMed
    11. Florenzano P, Ferreira C, Nesterova G, Roberts MS, Tella SH, de Castro LF, Brown SM, Whitaker A, Pereira RC, Bulas D, Gafni RI, Salusky IB, Gahl WA, Collins MT. Skeletal Consequences of Nephropathic Cystinosis. J Bone Miner Res. 2018 10; 33(10):1870-1880. PMID: 29905968.
      View in: PubMed
    12. Hanudel MR, Eisenga MF, Rappaport M, Chua K, Qiao B, Jung G, Gabayan V, Gales B, Ramos G, de Jong MA, van Zanden JJ, de Borst MH, Bakker SJL, Nemeth E, Salusky IB, Gaillard CAJM, Ganz T. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant. 2018 Jul 10. PMID: 30007314.
      View in: PubMed
    13. Hanudel MR, Laster M, Ramos G, Gales B, Salusky IB. Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients. Pediatr Nephrol. 2018 11; 33(11):2137-2142. PMID: 29956006.
      View in: PubMed
    14. Hanudel MR, Rappaport M, Chua K, Gabayan V, Qiao B, Jung G, Salusky IB, Ganz T, Nemeth E. Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica. 2018 04; 103(4):e141-e142. PMID: 29419424.
      View in: PubMed
    15. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Erratum to "Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease" [Bone, 45(6) (2009) 1161-1168]. Bone. 2018 03; 108:210-211. PMID: 29290423.
      View in: PubMed
    16. Mitsnefes MM, Betoko A, Schneider MF, Salusky IB, Wolf MS, Jüppner H, Warady BA, Furth SL, Portale AA. FGF23 and Left Ventricular Hypertrophy in Children with CKD. Clin J Am Soc Nephrol. 2018 01 06; 13(1):45-52. PMID: 29025789.
      View in: PubMed
    17. Demyan L, Harview C, Miller E, Wilkerson L, Salusky IB. Development of a translational research pathway at the David Geffen School of Medicine University of California, Los Angeles. Int J Med Educ. 2017 Sep 22; 8:334-335. PMID: 28949298.
      View in: PubMed
    18. Clinkenbeard EL, Hanudel MR, Stayrook KR, Appaiah HN, Farrow EG, Cass TA, Summers LJ, Ip CS, Hum JM, Thomas JC, Ivan M, Richine BM, Chan RJ, Clemens TL, Schipani E, Sabbagh Y, Xu L, Srour EF, Alvarez MB, Kacena MA, Salusky IB, Ganz T, Nemeth E, White KE. Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica. 2017 11; 102(11):e427-e430. PMID: 28818868.
      View in: PubMed
    19. Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 Sep 07; 12(9):1461-1469. PMID: 28705885.
      View in: PubMed
    20. Hanudel MR, Salusky IB. Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder. Curr Osteoporos Rep. 2017 06; 15(3):198-206. PMID: 28455644.
      View in: PubMed
    21. Hanudel MR, Froch L, Gales B, Jüppner H, Salusky IB. Fractures and Osteomalacia in a Patient Treated With Frequent Home Hemodialysis. Am J Kidney Dis. 2017 Sep; 70(3):445-448. PMID: 28495360.
      View in: PubMed
    22. Hanudel MR, Rappaport M, Gabayan V, Jung G, Salusky IB, Nemeth E, Ganz T, Zaritsky J. Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model. Haematologica. 2017 03; 102(3):e85-e88. PMID: 27884972.
      View in: PubMed
    23. Hanudel M, Jüppner H, Salusky IB. Fibroblast growth factor 23: fueling the fire. Kidney Int. 2016 11; 90(5):928-930. PMID: 27742194.
      View in: PubMed
    24. Laster M, Soohoo M, Hall C, Streja E, Rhee CM, Ravel VA, Reddy U, Norris KC, Salusky IB, Kalantar-Zadeh K. Racial-ethnic disparities in mortality and kidney transplant outcomes among pediatric dialysis patients. Pediatr Nephrol. 2017 04; 32(4):685-695. PMID: 27796622.
      View in: PubMed
    25. Hanudel MR, Chua K, Rappaport M, Gabayan V, Valore E, Goltzman D, Ganz T, Nemeth E, Salusky IB. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol. 2016 12 01; 311(6):F1369-F1377. PMID: 27733366.
      View in: PubMed
    26. Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clin J Am Soc Nephrol. 2016 11 07; 11(11):1989-1998. PMID: 27561289.
      View in: PubMed
    27. Nguyen KL, Yoshida T, Han F, Ayad I, Reemtsen BL, Salusky IB, Satou GM, Hu P, Finn JP. MRI with ferumoxytol: A single center experience of safety across the age spectrum. J Magn Reson Imaging. 2017 03; 45(3):804-812. PMID: 27480885.
      View in: PubMed
    28. Pereira RC, Andersen TL, Friedman PA, Tumber N, Salusky IB, Wesseling-Perry K. Correction: Bone Canopies in Pediatric Renal Osteodystrophy. PLoS One. 2016; 11(5):e0155663. PMID: 27167735.
      View in: PubMed
    29. Luhar A, Khan S, Finn JP, Ghahremani S, Griggs R, Zaritsky J, Salusky I, Hall TR. Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Pediatr Radiol. 2016 Aug; 46(9):1332-40. PMID: 27059620.
      View in: PubMed
    30. Pereira RC, Andersen TL, Friedman PA, Tumber N, Salusky IB, Wesseling-Perry K. Bone Canopies in Pediatric Renal Osteodystrophy. PLoS One. 2016; 11(4):e0152871. PMID: 27045269.
      View in: PubMed
    31. Bacchetta J, Salusky IB. Combining exercise and growth hormone therapy: how can we translate from animal models to chronic kidney disease children? Nephrol Dial Transplant. 2016 08; 31(8):1191-4. PMID: 26908776.
      View in: PubMed
    32. Pereira RC, Bischoff DS, Yamaguchi D, Salusky IB, Wesseling-Perry K. Micro-CT in the Assessment of Pediatric Renal Osteodystrophy by Bone Histomorphometry. Clin J Am Soc Nephrol. 2016 Mar 07; 11(3):481-7. PMID: 26712809.
      View in: PubMed
    33. Hanudel MR, Wesseling-Perry K, Gales B, Ramos G, Campbell V, Ethridge K, Scotti M, Elashoff DA, Alejos J, Reemtsen B, Salusky IB. Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients. Pediatr Nephrol. 2016 Apr; 31(4):661-9. PMID: 26525200.
      View in: PubMed
    34. Pereira RC, Valta H, Tumber N, Salusky IB, Jalanko H, Mäkitie O, Wesseling Perry K. Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation. PLoS One. 2015; 10(9):e0138156. PMID: 26390291.
      View in: PubMed
    35. Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, Salusky IB, Warady BA, Furth SL, Leonard MB. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol. 2016 Feb; 27(2):543-50. PMID: 26139439.
      View in: PubMed
    36. Pereira RC, Jüppner H, Gales B, Salusky IB, Wesseling-Perry K. Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients. PLoS One. 2015; 10(3):e0120856. PMID: 25774916.
      View in: PubMed
    37. Kaskel F, Salusky IB. Dr. Ira Greifer. Pediatr Nephrol. 2015 Apr; 30(4):699-700. PMID: 25620539.
      View in: PubMed
    38. Bacchetta J, Chun RF, Gales B, Zaritsky JJ, Leroy S, Wesseling-Perry K, Boregaard N, Rastogi A, Salusky IB, Hewison M. Antibacterial responses by peritoneal macrophages are enhanced following vitamin D supplementation. PLoS One. 2014; 9(12):e116530. PMID: 25549329.
      View in: PubMed
    39. Pereira RC, Delany AM, Khouzam NM, Bowen RE, Freymiller EG, Salusky IB, Wesseling-Perry K. Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo. Kidney Int. 2015 Mar; 87(3):593-601. PMID: 25354236.
      View in: PubMed
    40. Han F, Rapacchi S, Khan S, Ayad I, Salusky I, Gabriel S, Plotnik A, Finn JP, Hu P. Four-dimensional, multiphase, steady-state imaging with contrast enhancement (MUSIC) in the heart: a feasibility study in children. Magn Reson Med. 2015 Oct; 74(4):1042-9. PMID: 25302932.
      View in: PubMed
    41. Nayak AB, Luhar A, Hanudel M, Gales B, Hall TR, Finn JP, Salusky IB, Zaritsky J. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. Pediatr Nephrol. 2015 Mar; 30(3):515-21. PMID: 25212105.
      View in: PubMed
    42. Carvalho CG, Pereira RC, Gales B, Salusky IB, Wesseling-Perry K. Cortical and trabecular bone in pediatric end-stage kidney disease. Pediatr Nephrol. 2015 Mar; 30(3):497-502. PMID: 25185885.
      View in: PubMed
    43. Khouzam NM, Wesseling-Perry K, Salusky IB. The role of bone in CKD-mediated mineral and vascular disease. Pediatr Nephrol. 2015 Sep; 30(9):1379-88. PMID: 25168424.
      View in: PubMed
    44. Wesseling-Perry K, Wang H, Elashoff R, Gales B, Jüppner H, Salusky IB. Lack of FGF23 response to acute changes in serum calcium and PTH in humans. J Clin Endocrinol Metab. 2014 Oct; 99(10):E1951-6. PMID: 25062462.
      View in: PubMed
    45. Hanudel MR, Salusky IB, Zaritsky JJ. The accuracy of a continuous volumetric balancing system in pediatric continuous renal replacement therapy. Int J Artif Organs. 2014 Mar; 37(3):215-21. PMID: 24744166.
      View in: PubMed
    46. van Venrooij NA, Pereira RC, Tintut Y, Fishbein MC, Tumber N, Demer LL, Salusky IB, Wesseling-Perry K. FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol Dial Transplant. 2014 Aug; 29(8):1525-32. PMID: 24459137.
      View in: PubMed
    47. Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol. 2014 Feb; 9(2):344-53. PMID: 24311704.
      View in: PubMed
    48. Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, Salusky IB, Hewison M. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014 Mar; 25(3):564-72. PMID: 24204002.
      View in: PubMed
    49. Zaritsky J, Rastogi A, Fischmann G, Yan J, Kleinman K, Chow G, Gales B, Salusky IB, Wesseling-Perry K. Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis. Nephrol Dial Transplant. 2014 Feb; 29(2):437-41. PMID: 24009282.
      View in: PubMed
    50. Wesseling-Perry K, Pereira RC, Tsai E, Ettenger R, Jüppner H, Salusky IB. FGF23 and mineral metabolism in the early post-renal transplantation period. Pediatr Nephrol. 2013 Nov; 28(11):2207-15. PMID: 23852336.
      View in: PubMed
    51. Bacchetta J, Wesseling-Perry K, Kuizon B, Pereira RC, Gales B, Wang HJ, Elashoff R, Salusky IB. The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial. Clin J Am Soc Nephrol. 2013 May; 8(5):824-32. PMID: 23559676.
      View in: PubMed
    52. Wesseling-Perry K, Salusky IB. Chronic kidney disease: mineral and bone disorder in children. Semin Nephrol. 2013 Mar; 33(2):169-79. PMID: 23465503.
      View in: PubMed
    53. Bacchetta J, Wesseling-Perry K, Gilsanz V, Gales B, Pereira RC, Salusky IB. Idiopathic juvenile osteoporosis: a cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography. Pediatr Rheumatol Online J. 2013; 11:6. PMID: 23418950.
      View in: PubMed
    54. Wesseling-Perry K, Salusky IB. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children. Pediatr Nephrol. 2013 Apr; 28(4):617-25. PMID: 23381010.
      View in: PubMed
    55. Li J, Molnar MZ, Zaritsky JJ, Sim JJ, Streja E, Kovesdy CP, Salusky I, Kalantar-Zadeh K. Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrol Dial Transplant. 2013 Jun; 28(6):1516-25. PMID: 23348879.
      View in: PubMed
    56. Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, Adams JS, Salusky IB, Hewison M. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res. 2013 Jan; 28(1):46-55. PMID: 22886720.
      View in: PubMed
    57. Bellorin-Font E, Ambrosoni P, Carlini RG, Carvalho AB, Correa-Rotter R, Cueto-Manzano A, Jara A, Jorgetti V, Negri AL, Negri A, Olaizola I, Salusky I, Slatopolsky E, Weisinger JR. Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults. Nefrologia. 2013; 33 Suppl 1:1-28. PMID: 23629678.
      View in: PubMed
    58. Bacchetta J, Salusky IB, Hewison M. Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity? Pediatr Nephrol. 2013 Apr; 28(4):577-82. PMID: 23117582.
      View in: PubMed
    59. Griffin LM, Denburg MR, Shults J, Furth SL, Salusky IB, Hwang W, Leonard MB. Nutritional vitamin D use in chronic kidney disease: a survey of pediatric nephrologists. Pediatr Nephrol. 2013 Feb; 28(2):265-75. PMID: 23086591.
      View in: PubMed
    60. Miller JE, Molnar MZ, Kovesdy CP, Zaritsky JJ, Streja E, Salusky I, Arah OA, Kalantar-Zadeh K. Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoepidemiol Drug Saf. 2012 Nov; 21(11):1232-9. PMID: 22996597.
      View in: PubMed
    61. Molnar MZ, Kovesdy CP, Mucsi I, Salusky IB, Kalantar-Zadeh K. Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes. Clin J Am Soc Nephrol. 2012 Nov; 7(11):1859-71. PMID: 22956265.
      View in: PubMed
    62. Bacchetta J, Harambat J, Cochat P, Salusky IB, Wesseling-Perry K. The consequences of chronic kidney disease on bone metabolism and growth in children. Nephrol Dial Transplant. 2012 Aug; 27(8):3063-71. PMID: 22851629.
      View in: PubMed
    63. Padhi D, Langman CB, Fathallah-Shaykh S, Warady BA, Salusky IB, Lee E, Wang C, Posvar E. An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects. Pediatr Nephrol. 2012 Oct; 27(10):1953-9. PMID: 22639045.
      View in: PubMed
    64. Daugirdas JT, Chertow GM, Larive B, Pierratos A, Greene T, Ayus JC, Kendrick CA, James SH, Miller BW, Schulman G, Salusky IB, Kliger AS. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol. 2012 Apr; 23(4):727-38. PMID: 22362907.
      View in: PubMed
    65. Bacchetta J, Cochat P, Salusky IB, Wesseling-Perry K. Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function. Pediatr Nephrol. 2012 Jul; 27(7):1131-8. PMID: 22311343.
      View in: PubMed
    66. Bacchetta J, Salusky IB. Evaluation of hypophosphatemia: lessons from patients with genetic disorders. Am J Kidney Dis. 2012 Jan; 59(1):152-9. PMID: 22075221.
      View in: PubMed
    67. Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, Sahney S, Gales B, Jüppner H, Salusky IB. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012 Jan; 7(1):146-52. PMID: 22052943.
      View in: PubMed
    68. Wesseling-Perry K, Tsai EW, Ettenger RB, Jüppner H, Salusky IB. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant. 2011 Nov; 26(11):3779-84. PMID: 21441401.
      View in: PubMed
    69. Jüppner H, Wolf M, Salusky IB. FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res. 2010 Oct; 25(10):2091-7. PMID: 20593414.
      View in: PubMed
    70. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Jüppner H, Salusky IB. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011 Jan; 79(1):112-9. PMID: 20861820.
      View in: PubMed
    71. Rianthavorn P, Ettenger RB, Salusky IB, Kuizon BD. Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium. Pediatr Nephrol. 2010 Nov; 25(11):2311-9. PMID: 20676692.
      View in: PubMed
    72. Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, Salusky IB. Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol. 2010 Oct; 5(10):1860-6. PMID: 20634327.
      View in: PubMed
    73. Zaritsky JJ, Salusky IB. Ironing out the phosphorus problem. Kidney Int. 2010 May; 77(10):845-7. PMID: 20431575.
      View in: PubMed
    74. Wesseling-Perry K, Harkins GC, Wang HJ, Elashoff R, Gales B, Horwitz MJ, Stewart AF, Jüppner H, Salusky IB. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). J Clin Endocrinol Metab. 2010 Jun; 95(6):2772-80. PMID: 20382692.
      View in: PubMed
    75. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol. 2010 Jun; 5(6):1010-4. PMID: 20299375.
      View in: PubMed
    76. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Jüppner H. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010 Feb; 95(2):578-85. PMID: 19965919.
      View in: PubMed
    77. Amin N, Gonzalez E, Lieber M, Salusky IB, Zaritsky JJ. Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient. Pediatr Nephrol. 2010 Feb; 25(2):357-62. PMID: 19885686.
      View in: PubMed
    78. Gonzalez E, Schomberg J, Amin N, Salusky IB, Zaritsky J. Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr Nephrol. 2010 Feb; 25(2):373-5. PMID: 19876653.
      View in: PubMed
    79. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009 Dec; 45(6):1161-8. PMID: 19679205.
      View in: PubMed
    80. Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thadhani RI, Chiu YW, Martins D, Adler SG, Norris KC. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009 Nov; 76(9):977-83. PMID: 19657329.
      View in: PubMed
    81. Wesseling-Perry K, Salusky IB. Is replacement therapy with nutritional and active forms of vitamin D required in chronic kidney disease mineral and bone disorder? Curr Opin Nephrol Hypertens. 2009 Jul; 18(4):308-14. PMID: 19458529.
      View in: PubMed
    82. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009 Jun; 4(6):1051-6. PMID: 19406957.
      View in: PubMed
    83. Wesseling-Perry K, Harkins GC, Wang HJ, Sahney S, Gales B, Elashoff RM, Jüppner H, Salusky IB. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatr Nephrol. 2009 Jul; 24(7):1355-61. PMID: 19301038.
      View in: PubMed
    84. Langman CB, Alon U, Ingelfinger J, Englund M, Saland JM, Somers MJ, Stapleton FB, Sibú NO, Cochat P, Wong W, Eke FU, Satlin L, Salusky I. A position statement on kidney disease from powdered infant formula-based melamine exposure in Chinese infants. Pediatr Nephrol. 2009 Jul; 24(7):1263-6. PMID: 19198884.
      View in: PubMed
    85. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Jüppner H, Salusky IB. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab. 2009 Feb; 94(2):511-7. PMID: 19050056.
      View in: PubMed
    86. Hernandez JD, Wesseling K, Pereira R, Gales B, Harrison R, Salusky IB. Technical approach to iliac crest biopsy. Clin J Am Soc Nephrol. 2008 Nov; 3 Suppl 3:S164-9. PMID: 18988702.
      View in: PubMed
    87. Salusky IB, Cohen P. Lost in translation? Pediatr Res. 2008 Sep; 64(3):225. PMID: 18714199.
      View in: PubMed
    88. Zaritsky JJ, Salusky IB, Gales B, Ramos G, Atkinson J, Allsteadt A, Brandt ML, Goldstein SL. Vascular access complications in long-term pediatric hemodialysis patients. Pediatr Nephrol. 2008 Nov; 23(11):2061-5. PMID: 18712416.
      View in: PubMed
    89. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Norris K. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol. 2008 Jul; 3(4):1144-51. PMID: 18417740.
      View in: PubMed
    90. Zurowska A, Feneberg R, Warady BA, Zimmering M, Monteverde M, Testa S, Calyskan S, Drozdz D, Salusky I, Kemper MJ, Ekim M, Verrina E, Misselwitz J, Schaefer F. Gram-negative peritonitis in children undergoing long-term peritoneal dialysis. Am J Kidney Dis. 2008 Mar; 51(3):455-62. PMID: 18295061.
      View in: PubMed
    91. Wesseling K, Bakkaloglu S, Salusky I. Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol. 2008 Feb; 23(2):195-207. PMID: 18046581.
      View in: PubMed
    92. Wesseling K, Salusky IB. Vitamin D therapy in children on dialysis. Perit Dial Int. 2007 Nov-Dec; 27(6):651-3. PMID: 17984426.
      View in: PubMed
    93. Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis. 2007 Jun; 49(6):814-23. PMID: 17533024.
      View in: PubMed
    94. Hernandez JD, Wesseling K, Boechat MI, Gales B, Salusky IB. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol. Nat Clin Pract Nephrol. 2007 Apr; 3(4):227-32. PMID: 17389892.
      View in: PubMed
    95. Salusky IB. A new era in phosphate binder therapy: what are the options? Kidney Int Suppl. 2006 Dec; (105):S10-5. PMID: 17136110.
      View in: PubMed
    96. Wesseling K, Salusky IB. Current treatment options in secondary hyperparathyroidism. Nephrol Dial Transplant. 2006 Oct; 21(10):2986-7; author reply 2989-90. PMID: 16861736.
      View in: PubMed
    97. Chesney RW, Brewer E, Moxey-Mims M, Watkins S, Furth SL, Harmon WE, Fine RN, Portman RJ, Warady BA, Salusky IB, Langman CB, Gipson D, Scheidt P, Feldman H, Kaskel FJ, Siegel NJ. Report of an NIH task force on research priorities in chronic kidney disease in children. Pediatr Nephrol. 2006 Jan; 21(1):14-25. PMID: 16252095.
      View in: PubMed
    98. Hernandez JD, Wesseling K, Salusky IB. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin Dial. 2005 Jul-Aug; 18(4):290-5. PMID: 16076350.
      View in: PubMed
    99. Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, Elashoff RM, Jüppner H. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol. 2005 Aug; 16(8):2501-8. PMID: 15944337.
      View in: PubMed
    100. Qiao JH, Doherty TM, Fishbein MC, Salusky IB, Luthringer DL, Fitzpatrick LA, Shah PK, Rajavashisth TB. Calcification of the coronary arteries in the absence of atherosclerotic plaque. Mayo Clin Proc. 2005 Jun; 80(6):807-9. PMID: 15948300.
      View in: PubMed
    101. Greenbaum LA, Grenda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol. 2005 May; 20(5):622-30. PMID: 15785941.
      View in: PubMed
    102. Salusky IB. Are new vitamin D analogues in renal bone disease superior to calcitriol? Pediatr Nephrol. 2005 Mar; 20(3):393-8. PMID: 15690188.
      View in: PubMed
    103. Salusky IB, Jüppner H. New PTH assays and renal osteodystrophy. Pediatr Nephrol. 2004 Jul; 19(7):709-13. PMID: 15173936.
      View in: PubMed
    104. Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, Malluche HH, McCarthy JT, Massry SG, Mehls O, Salusky IB, Silver JM, Smogorzewski MT, Slatopolsky EM, McCann L. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004 Mar; 43(3):558-65. PMID: 14981615.
      View in: PubMed
    105. Freundlich M, Jofe M, Goodman WG, Salusky IB. Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. Pediatr Nephrol. 2004 Apr; 19(4):400-7. PMID: 14991389.
      View in: PubMed
    106. Salusky IB, Kuizon BG, Jüppner H. Special aspects of renal osteodystrophy in children. Semin Nephrol. 2004 Jan; 24(1):69-77. PMID: 14730512.
      View in: PubMed
    107. Lapeyraque AL, Haddad E, André JL, Brémond-Gignac D, Taylor CM, Rianthavorn P, Salusky IB, Loirat C. Sudden blindness caused by anterior ischemic optic neuropathy in 5 children on continuous peritoneal dialysis. Am J Kidney Dis. 2003 Nov; 42(5):E3-9. PMID: 14582071.
      View in: PubMed
    108. Mahdavi H, Kuizon BD, Gales B, Wang HJ, Elashoff RM, Salusky IB. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol. 2003 Dec; 18(12):1260-4. PMID: 14586677.
      View in: PubMed
    109. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Jüppner H. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003 May; 63(5):1801-8. PMID: 12675856.
      View in: PubMed
    110. Lima EM, Goodman WG, Kuizon BD, Gales B, Emerick A, Goldin J, Salusky IB. Bone density measurements in pediatric patients with renal osteodystrophy. Pediatr Nephrol. 2003 Jun; 18(6):554-9. PMID: 12712376.
      View in: PubMed
    111. Oppenheim WL, Bowen RE, McDonough PW, Funahashi TT, Salusky IB. Outcome of slipped capital femoral epiphysis in renal osteodystrophy. J Pediatr Orthop. 2003 Mar-Apr; 23(2):169-74. PMID: 12604945.
      View in: PubMed
    112. Goodman WG, Jüppner H, Salusky IB, Sherrard DJ. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int. 2003 Jan; 63(1):1-11. PMID: 12472763.
      View in: PubMed
    113. Goodman WG, Salusky IB, Jüppner H. New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments. Nephrol Dial Transplant. 2002 Oct; 17(10):1731-6. PMID: 12270977.
      View in: PubMed
    114. Kuizon BD, Salusky IB. Cell biology of renal osteodystrophy. Pediatr Nephrol. 2002 Oct; 17(10):777-89. PMID: 12376803.
      View in: PubMed
    115. Imanishi Y, Tahara H, Palanisamy N, Spitalny S, Salusky IB, Goodman W, Brandi ML, Drüeke TB, Sarfati E, Ureña P, Chaganti RS, Arnold A. Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol. 2002 Jun; 13(6):1490-8. PMID: 12039978.
      View in: PubMed
    116. Sanchez CP, Kuizon BD, Goodman WG, Gales B, Ettenger RB, Boechat MI, Wang Y, Elashoff R, Salusky IB. Growth hormone and the skeleton in pediatric renal allograft recipients. Pediatr Nephrol. 2002 May; 17(5):322-8. PMID: 12042887.
      View in: PubMed
    117. Chan JC, Roth KS, Salusky IB. Clinical research and training: an overview. J Pediatr. 2002 Mar; 140(3):293-8. PMID: 11953725.
      View in: PubMed
    118. Salusky IB, Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant. 2002 Feb; 17(2):336-9. PMID: 11812902.
      View in: PubMed
    119. Salusky IB. PTH assays in renal failure. Semin Dial. 2002 Jan-Feb; 15(1):73. PMID: 11874600.
      View in: PubMed
    120. Salusky IB, Goodman WG. Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol. 2001 Sep; 12(9):1978-85. PMID: 11518793.
      View in: PubMed
    121. Salusky IB, Goodman WG, Kuizon BD. Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism. Pediatr Nephrol. 2000 Jul; 14(7):641-5. PMID: 10912534.
      View in: PubMed